On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
The hospital is being constructed at an estimated cost of around Rs. 6,000 crore and will provide healthcare facilities to the people of Faridabad and the entire NCR region
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Company creates Younger T Cells for fighting cancer using its NR2F6 technology
Capnomed successfully introduced the medical device Capnopen, the gold standard of laparoscopic nebulizers.
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Tislelizumab is now approved in nine indications in China
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Subscribe To Our Newsletter & Stay Updated
